FreePeptideCalc

Semaglutide with Methylcobalamin (B12): What the FDA Actually Says

The FDA has a direct statement about combining semaglutide with vitamin B12, and it is not the one the marketing implies. No trial of the combination has ever been published.

Written by , who builds and maintains this site and is not a clinician. Every figure links to its primary source. · Last reviewed

The FDA has already published a position on this exact combination, and it is short. From its compounding statement: FDA may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available drug product when the drug products are used by the same route of administration — the compounded product is given the same way as the commercially available ones, such as an injectable — and are the same, similar or easily substitutable strength, meaning the amounts of semaglutide and vitamin B12 are within 10% of the strengths of the respective commercially available drug products.

Read that against the usual sales line — that adding B12 makes the product something other than a copy of Ozempic or Wegovy — and the two do not agree. The FDA wrote the semaglutide-plus-B12 combination into its guidance as the worked example of a product it may still consider a copy.

Why this became a question in 2025

Large-scale compounding of semaglutide existed because of a shortage. That shortage is over. FDA determined the shortage of semaglutide injection products resolved on 21 February 2025; the tirzepatide injection shortage had already been declared resolved on 19 December 2024.

Once supply is not the justification, the question shifts to whether a compounded product is essentially a copy of an approved one — which is where the added ingredient argument came from, and which is the argument the FDA addressed directly.

Compounded drugs are not approved by FDA. In the agency’s own words, FDA-approved drugs go through FDA’s rigorous review for safety, effectiveness and quality as part of the premarket approval process. A compounded semaglutide product — with or without B12 — has not been through that review before it reaches you.

Methylcobalamin is not the B12 the FDA named

This is the detail the search term hides. The FDA’s example says vitamin B12 (cyanocobalamin). Cyanocobalamin and methylcobalamin are different chemical forms, and their regulatory positions are not the same.

Form of B12US statusWhat that rests on
Cyanocobalaminthe form named in the FDA's own exampleApproved drug productCyanocobalamin injection holds an approved ANDA and is marketed as a prescription product.
MethylcobalaminNot approvedthe form in the search termNo approved drug productNo matches in Drugs@FDA. Listed on the FDA 503A bulks list under Category 1 — under evaluation.

Drugs@FDA searched for each ingredient on 17 September 2026. The 503A entry is from the bulk drug substances list updated 14 May 2026.

Category 1 on the 503A bulks list means exactly what its heading says — bulk drug substances under evaluation. It is a holding status while the FDA assesses a substance, not a conclusion that it is safe, effective or approved. This site makes the same point about other substances that people read as approved because they appear on a list.

The reason given for adding B12, checked

The rationale offered is consistent: semaglutide suppresses appetite, people eat less, so micronutrient intake falls and B12 gets topped up in the same injection. Part of that is supported and part of it is not, and the two parts are worth separating.

Supported: a 2026 narrative review in Obesity Pillars on micronutrient risk during GLP-1 and dual incretin therapy lists vitamin B12 among the relevant signals, alongside iron, vitamin D, calcium, magnesium and zinc. It attributes the risk to reduced food intake, lower dietary diversity, gastrointestinal intolerance, delayed gastric emptying, rapid weight loss and baseline nutritional risk.

Not supported: that review also states that most abnormalities reported to date are subclinical or indirect, and concludes that prospective studies are needed to define incidence, clinical relevance and evidence-based monitoring strategies. Its recommendation is individualised assessment and targeted laboratory monitoring for high-risk patients — which is a blood test, not an additive in the syringe.

There is no trial of the combination

This is the finding, and it is worth stating as bluntly as the sourcing allows. Searched on 17 September 2026:

  • ClinicalTrials.gov returned two interventional studies for semaglutide together with cyanocobalamin, methylcobalamin or vitamin B12. Neither is a trial of a combined semaglutide-plus-B12 product.
  • PubMed returned ten records for the same terms. None is a trial of the combination — they are a case report of nutritional neuropathy after semaglutide gastrointestinal intolerance, the micronutrient review above, papers on post-bariatric nutrition, and several unrelated to either subject.

So there is no published evidence that the combined product works better than semaglutide alone, no published evidence that it reduces nausea, and no published evidence that it improves energy or tolerability. Not weak evidence. None. Anyone telling you otherwise is describing something that has not been measured.

There is also no published pharmacokinetic or stability data for the mixed product that we could find — no reliable source, so no figure is published here.

What is actually established

  • Semaglutide is approved and its schedule is published. The approved products carry a titration schedule, a strength and a route in the label, none of which changes because a second ingredient is added. Semaglutide dosing and sources.
  • B12 deficiency is diagnosable. It is a blood test with a treatment path that does not require it to share a syringe with a GLP-1.
  • FDA has an open concern with unapproved GLP-1 products. Its standing alert on unapproved GLP-1 drugs used for weight loss covers dosing errors and products of unknown provenance, independently of the copy question.
Nothing on this page is a reason to stop a prescribed medicine. If you are taking a compounded semaglutide product that contains B12, the useful next step is asking the prescriber which form of B12 it contains, at what strength, and what it is being monitored against — those are answerable questions, and the answers are more informative than anything a page can tell you about a product it has not seen.

Related

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

  1. RegulatorFDA· 2026-04-01
    FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
  2. RegulatorFDA· 2026-05-14
    Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
  3. RegulatorFDA· 2026-09-01
    FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
  4. Published studyObesity Pillars· 2026-06
    Simancas-Racines D et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: mechanistic pathways, clinical signals, and a monitoring framework
  5. ReferenceFDA / CDER
    Drugs@FDA: FDA-Approved Drugs — searchable database of approved applications and products
  6. ReferenceU.S. National Library of Medicine
    ClinicalTrials.gov trial registry
  7. ReferenceNIH / National Library of Medicine
    PubMed — biomedical literature database